Recently, Maximum Biology was once again recognized as one of the “Top 100 Chinese Pharmaceutical Innovation Seed Companies in 2026,” a list launched and published by EYao Manager. This marks the fourth consecutive year that the company has received this honor. For an innovative pharmaceutical company that has long focused on universal CAR-T therapies and prioritized its initial launch in extremely challenging areas such as recurrent glioma, this recognition not only affirms its phased R&D achievements but also documents the persistent progress of a team addressing critical, long-term clinical needs through innovation and perseverance.Maximum Biology Named Among “Top 100 Seed Enterprises in China’s Pharmaceutical Innovation 2026”Gliomas, particularly recurrent glioblastoma, represent one of the most challenging frontiers in oncology. These tumors arise within the human body’s most intricate and fragile organ, presenting biological hurdles such as the blood-brain barrier, tumor heterogeneity, and an immunosuppressive microenvironment, alongside clinical challenges including preservation of neurological function, control of local inflammation, and selection of optimal delivery routes. Therapeutic efficacy must be sufficiently potent to suppress rapidly progressing tumors, while safety profiles must be meticulously refined to avoid compromising patients’ precious neurological functions. This R&D endeavor is akin to dancing on tofu: every step requires both strength and precision.Under the leadership of Dr. Shang Xiaoyun, Maximum Biology has not chosen the most crowded and easily understandable direction, but instead firmly targets real and urgent clinical hard needs. The company focuses on its B7-H3-targeted universal CAR-T product MT027 as the core.Focusing on recurrent gliomas, and extending to intracranial solid tumors such as brain metastases.This choice was not an easy one, yet it points to the most fundamental value judgment in innovative drug development:Where patients lack effective options, there is a greater need for individuals to systematically deconstruct scientific, engineering, and clinical issues.Over the past few years, Maximum Biology has continuously advanced the exploration of MT027 through investigator-initiated clinical studies. The team has boldly hypothesized and rigorously validated:From target selection, local administration routes, dosing and administration schedules, to cell manufacturing processes, companion diagnostics, and safety monitoring systems,Every step has been repeatedly refined around the two key principles of “efficacy and safety.” Existing IIT data show that,MT027 demonstrated positive survival signals in 14 patients with recurrent glioblastoma, with a median overall survival of approximately 15.9 months;In terms of safety, the profile was characterized primarily by low-grade inflammation and monitorable responses, with no confirmed signals of severe CAR-T-related cytokine release syndrome (CRS) or other serious adverse events. For high-risk indications such as brain tumors, such progress is hard-won and necessitates a cautious and standardized advancement to the next phase of validation.Maximum Biology’s adherence to the principle that “slow is fast” does not mean slowing down innovation, but rather maintaining sufficient reverence in the face of life.Innovative drug development is not about articulating concepts more rapidly, but about building more robust evidence; it is not about downplaying risks, but about conducting more meticulous risk identification, management, and validation.Centered on MT027,Maximum Biology continues to advance the iteration of non-viral gene editing processes, quality control systems, clinical protocols, and international registration pathways.Striving to develop a cell therapy product for extremely refractory solid tumors that embodies both the courage to push beyond disease boundaries and the robustness to withstand clinical and regulatory scrutiny.This path is not only difficult in terms of science.For zero-to-one innovative projects, funding, resources, and trust are daily tests. Throughout the journey, the management team at Maximum Biology has repeatedly explained to investors the product prospects, clinical value, and technical pathways, while also enduring the skepticism common to early-stage projects:Can CAR-T therapy be successfully developed for solid tumors? Is glioma too challenging a target? Can universal cell therapies find a window between safety and efficacy?To ensure the company’s operational continuity and the steady advancement of its innovative drug projects, the team raised funds through various means, including credit guarantees, mortgage loans on properties, and borrowings from relatives and friends; meanwhile, senior management took the lead in reducing salaries and deferring wage payments.Difficult times were not packaged into slogans, but broken down into individual practical problems that needed to be solved.Recently, a series of milestones have given clearer resonance to this long-term persistence.MT027 Receives U.S. FDA Phase II Clinical Trial Approval for Recurrent Glioblastomaand subsequent clinical development has been initiated;The early clinical data of the company’s other glioma-related pipeline, MT026, were published in Nature Communications.Demonstrating favorable safety profiles and preliminary anti-tumor activity; coupled with its selection for the fourth consecutive year among the “Top 100 Seed Enterprises in China’s Pharmaceutical Innovation,” Maximum Biology is progressively translating its years of accumulated Investigator-Initiated Trial (IIT) experience, process innovations, and clinical protocol explorations into phased achievements that are visible to the industry, verifiable by regulators, and anticipated by patients.Selected for four consecutive years, not an endpoint, but a reminder:Truly valuable innovations often emerge in the most difficult, slowest, and least readily understood areas in the short term.Maximum Biology will continue to be guided by clinical needs, supported by technological innovation, and grounded in a profound reverence for humanity and life, steadily advancing the clinical development of MT027 and its subsequent pipeline. Facing the battlefield of brain tumors, where there are virtually no shortcuts, the company aims to answer the most critical question with evidence that is reproducible, auditable, and translatable:Can it bring longer-lasting and safer benefits to patients who are still waiting for new options?First Review | Shi Wanjia
Second Review | Li Fangchen
Third Review | Li Jingzhi
